INTRODUCTION AND OBJECTIVES: Renal mass biopsy (RMB) can be employed as an adjunct to the decision-making process for patients with small renal masses. It is hypothesized that the pathological diagnosis provided by RMB purports a QOL advantage by alleviating cancer-related uncertainty and anxiety. This study evaluates the influence of RMB on QOL in a large prospective registry of patients with SRM.
INTRODUCTION AND OBJECTIVES: Renal mass biopsy (RMB) can be employed as an adjunct to the decision-making process for patients with small renal masses. It is hypothesized that the pathological diagnosis provided by RMB purports a QOL advantage by alleviating cancer-related uncertainty and anxiety. This study evaluates the influence of RMB on QOL in a large prospective registry of patients with SRM.
METHODS: The DISSRM (Delayed Intervention and Surveillance for Small Renal Masses) Registry is a multi-institutional study that prospectively follows patients with SRM who elect primary intervention (PI) or active surveillance (AS). Patients complete SF12 QOL questionnaire at enrollment, 6 and 12 months, and subsequently on an annual basis. SF12 scores, MCS (Mental Component Summary) and PCS (Physical Component Summary) were compared between patients who had RMB versus those who did not in the PI, AS, and crossover groups separately using ANOVA and linear regression mixed modeling. RESULTS: 619 patients were identified in the DISSRM Registry, of whom 320 were in the AS arm and 299 in the PI arm. 84 patients (13.6%) underwent biopsy, 34 (40.6%) in the PI group, 35 (41.6%) in the AS group, and 15 (17.8%) in the AS group who crossed over. Median age, ECOG performance status and Charlson comorbidity Index (CCI) were similar regardless of biopsy status among the AS and PI groups. In PI patients, there were no significant differences between SF12, MCS or PCS (p>0.092) or changes in SF12, MCS, or PCS (p>0.162) in patients who underwent biopsy and those who did not across all time points up to 84 months. In the AS patients who did not crossover, no differences in SF12, MCS and PCS were seen between patients who had biopsy and those who did not (p>0.0564). PCS declined over time in patients who stayed on AS without biopsy (p<0.001), but all other measures were unchanged over time (p>0.7291). In the crossover group, SF12, MCS, and PCS were lower at 24 and 48 months in patients who had not undergone biopsy (p¼0.002). These patients were older (72.5 vs 67.2, p¼0.003), had higher CCI (p¼0.004), and lower ECOG performance status (p¼0.045). There were no changes to SF12, MCS, or PCS scores in crossover patients regardless of biopsy status over time (p>0.1513).
CONCLUSIONS: AS and PI patients who underwent RMB during follow-up in DISSRM did not have significant changes in quality of life scores over time, nor did they have worse scores than their counterparts who did not undergo biopsy. A pathological diagnosis through RMB did not appear to have a beneficial or detrimental effect on QOL while on AS. 
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INTRODUCTION AND OBJECTIVES:
A considerable proportion of small renal masses (SRMs) are either benign or demonstrate indolent behavior, yet guidelines stop short of recommending active surveillance (AS) over definitive treatment for any subset of patients with SRMs. Because coding does not easily capture AS, outcomes data is limited and secondary data analysis is difficult. Given these limitations, we developed a mathematical model to determine when AS can be recommended over definitive treatment.
METHODS: We developed a Markov Decision Process (MDP) model to maximize life years and quality-adjusted life years (QALYs) for patients with SRMs over a ten year horizon, comparing AS, ablation, and surgical treatments. Patient demographics, pre-existing comorbidities, mass characteristics, degree of renal impairment, and treatmentassociated morbidity were incorporated. A Markov model was used to simulate the size progression of SRMs. All model inputs were extrapolated from current literature.
RESULTS: Table 1 shows results for one patient subset: 65 year old patients with no comorbidities. To maximize life years, the model recommended AS over definitive treatment for patients with SRMs up to 3 cm in diameter. Partial nephrectomy (PN) was recommended for patients with masses 3 cm and larger. Ablation was recommended as a secondary option to PN due to the assumption of a higher recurrence rate with ablation compared to PN. For patients with a central mass where nephron sparring treatment was less feasible, radical nephrectomy (RN) was only recommended for patients with 4 cm masses and larger without advanced chronic kidney disease (CKD Stage 4 and 5). To maximize QALYs, the model recommended AS for more subsets of patients, including older patients.
CONCLUSIONS: Clinicians are increasingly advising patients with SRMs to undergo active surveillance over definitive treatment. In the absence of large prospective trials, mathematical modeling can help frame the decision making process for patients and inform future guidelines on the management of patients with SRMs. Our model can give personalized recommendations for patients based on demographics, comorbidities, and mass characteristics. INTRODUCTION AND OBJECTIVES: Overtreatment of older patients with a small renal mass is a relevant concern and active surveillance [AS] represents an attractive management. However, current criteria for AS eligibility lack of validation. The aim of the study was to Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1135 validate a criterion for AS eligibility based on tumour clinical size and age on a cohort of patients treated with surgery. METHODS: 1922 patients diagnosed with a cT1cN0cM0 renal mass elected for surgical treatment and collected into a prospective database were assessed. Under the assumption that older patients with smaller tumours are optimal candidates for AS relative to younger patients with larger tumours, we relied on the ratio [R] between tumour clinical size and age in order to differentiate patients suitable for AS (R<5) from patients unsuitable for AS (R5). X2 test was used to compare the rate of malignant histology, stage pT3-pT4 and grade G3-G4 at final pathology in patients suitable vs. unsuitable for AS.
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Smoothed Poisson's incidence plots were used to examine the rate of cancer specific [CSM] and other cause mortality [OCM] in patients suitable vs. unsuitable for AS.
RESULTS: According to the proposed definition, the rate of patients suitable for AS was 34%. Patient suitable for AS had a lower rate of malignant histology (78 vs. 87%; p<0.001), pT3-pT4 (4 vs. 10% p¼0.001) and grade G3-G4 (7 vs. 17% p<0.001) relative to patients unsuitable for AS. In patients suitable for AS, the 10-year rates of CSM and OCM were 1.7 and 19%, respectively (Fig. 1A) . In patients unsuitable for AS, the 10-year rates of CSM and OCM were 6.7 and 11% (Fig. 1B) , respectively. CONCLUSIONS: When validated in a cohort of surgically treated patients, the ratio between tumour clinical size and age is a useful parameter to differentiate patients with adverse pathologic outcomes from patients with more favourable pathologic outcomes. These differences translate into critically different relative rates of CSM and OCM. These findings suggest that the proposed strategy criterion deserve further examination as a potential criterion for AS.
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PD59-09 MANAGEMENT OF SMALL RENAL MASSES IN RENAL TRANSPLANT RECIPIENT CANDIDATES: A MULTI-INSTITUTIONAL SURVEY ANALYSIS
Alp Tuna Beksac*, David Paulucci, John Sfakianos, Balaji Reddy, Susan Lerner, Jared Winoker, Harry Anastos, Jorge Pereira, Ketan Badani, New York, NY INTRODUCTION AND OBJECTIVES: Radical nephrectomy (RN) is the preferred treatment of small renal masses (SRM) in renal transplant candidates. Given the high risk of surgical complications in this cohort, active surveillance (AS) may be an option as many lesions are indolent. Since data on the use of AS in this setting is lacking, we surveyed transplant surgeons across the US on their institutional practice patterns for treatment of SRM.
METHODS: A 21-question online survey designed to analyze practice patterns of SRM management in renal transplant recipient candidates was sent to active transplant centers in the US. The list of recipients to whom the survey was distributed was obtained with permission from the American Society of Transplant Surgeons. All respondents were de-identified and consented to participate.
RESULTS:
We received 62 responses from 53 US Transplant Centers. All 11 United Network of Organ Sharing (UNOS) regions were represented. 38.7% (n¼24) indicated that their institution does not follow formal guidelines for treatment of SRM. The majority (85.5%, n¼53) indicated that their institution screens for renal masses in candidates for renal transplantation. RN was the preferred treatment (59%, n¼61), followed by AS (21.3%, n¼13), partial nephrectomy (14.8%, n¼9) and focal ablative therapy (4.9%, n¼3). Additionally, 14.5% (n¼9) respondents routinely perform renal mass biopsy before any decision is made. Although the majority of centers prefer definitive treatment, 27% allow AS prior to transplantation. For those institutions that allow AS, 95.5% felt comfortable if mass was <1 cm, 41.7% if <2 cm and 20.8% if 2-4 cm. Among institutions that allow AS, none alter their immunosuppressive regimen. Amongst the responders whose institutions did not allow active surveillance, 77.4% indicated that if presented with longterm data showing safety of AS, they would perform immediate transplantation and monitor SRM in these patients.
CONCLUSIONS: Variations in practice patterns suggest the need for standardized guidelines in the management of SRM in renal transplant candidates. Though RN is the preferred treatment, most transplant surgeons would consider AS if long term safety data were available.
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PD59-10 THE NATURAL HISTORY OF LARGE RENAL MASSES ON ACTIVE SURVEILLANCE & EXPECTANT MANAGEMENT
Karim Marzouk*, Amy Tin, Nick Liu, Daniel Sjoberg, A. Ari Hakimi, Paul Russo, Jonathan Coleman, New York City, NY INTRODUCTION AND OBJECTIVES: Surgical intervention is the standard of care for large renal masses; however patients with competing risks may not be suitable candidates for immediate intervention. This study illustrates our experience with active surveillance (AS) and expectant management of large renal masses (LRM) 4cm. We describe the growth rate of LRM under surveillance, factors associated with growth rate, and overall outcomes.
METHODS: Our institutional database identified 101 patients with renal masses 4.0cm between 1993 and 2016. Inclusion criteria were those followed with serial imaging for at least 6 months without surgical intervention. Bosniak 1-2 cysts and clinically benign renal masses such as angiomyolipomas were excluded from analysis. We used ordinal least squares regression to calculate LRM growth rate (cm/ year) for each patient based on maximal diameter. Univariate linear regression was used to assess whether clinical factors were associated with growth rate and competing risk methods were used to estimate the probability of developing RCC metastasis in the setting of death from other causes.
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